Core Viewpoint - The company, along with InstilBio, Inc., announced updates on the clinical status and future plans for IMM2510/AXN-2510, particularly focusing on its application in treating non-small cell lung cancer (NSCLC) Group 1: Clinical Trial Updates - The Phase 2 trial for IMM2510/AXN-2510 in combination with chemotherapy for first-line NSCLC is expected to complete patient enrollment of approximately 60 patients by Q3 2025 in China [1] - As of the end of March 2025, over 30 NSCLC patients have been enrolled, with more than 20 first-line NSCLC patients having received treatment [1] - Preliminary safety and efficacy results from this Phase 2 trial are anticipated to be announced in the second half of 2025 [1] Group 2: Single-Agent Treatment Data - The objective response rate (ORR) for IMM2510/AXN-2510 as a monotherapy for recurrent/refractory NSCLC is reported to be 23%, based on a data set similar to that of a competing PD-(L)1x VEGF bispecific antibody [2] Group 3: Future Clinical Plans - The company plans to initiate a Phase 3 trial for IMM2510/AXN-2510 in combination with chemotherapy for first-line NSCLC in mid-2026, pending discussions with regulatory authorities [3] - Preclinical experiments have demonstrated that IMM2510/AXN-2510 can synergistically bind with PD-L1 in the presence of VEGF in vitro [3] - Additional preclinical data indicating a potentially best-in-class mechanism of action for IMM2510/AXN-2510 is expected to be presented at future medical or scientific conferences [3]
宜明昂科-B(01541.HK)预计2025年第三季在中国完成IMM2510/AXN-2510联合化疗治疗一线NSCLC患者2期试验约60名患者入组